ARI Pune's Nanomedicine Silences Breast-Cancer 'Survival Genes'

India's Department of Science and Technology has put a homegrown gene-silencing nanomedicine on the board. Around 3 June 2026, its Agharkar Research Institute (ARI) in Pune unveiled a biodegradable mesoporous-silica nanocarrier that delivers two gene-silencing siRNA molecules into breast-cancer cells, switching off the genes the cancer uses to survive and causing tumour regression in animal models with what the institute described as minimal systemic toxicity. The work, led by Virendra Gajbhiye of ARI's Nanobioscience Group, was published in Advanced Healthcare Materials.

How it works

The therapy rests on siRNA, short interfering RNA, which can switch off a specific gene by intercepting and destroying the messenger RNA that carries its instructions from DNA to the cell's protein-making machinery. In principle, siRNA is the most precise drug imaginable: tell it the gene, and it silences that gene and no other. In practice it is almost useless on its own in the body. It is fragile, degrades within minutes in the bloodstream, is filtered out by the kidneys, and cannot cross the cell membrane unaided. Delivery is the entire problem, and it is the reason siRNA took decades to reach the clinic despite its conceptual elegance.

The nanocarrier is the solution to that delivery problem, and it is where the real engineering lives.

The nanocarrier, engineered

ARI's carrier is a small masterpiece of nano-design. It is a mesoporous silica particle, a speck of glass riddled with a regular array of tiny pores that hold the drug cargo, chosen because it is stable, biodegradable and can pack a large payload into its pores. The particle is modified with protamine and capped so that it stays sealed while travelling through the body, preventing the siRNA from leaking out and degrading before it arrives.

Two features make it smart rather than merely protective. First, it is decorated with a MUC1 aptamer, a short folded strand of nucleic acid that recognises and binds the MUC1 protein over-displayed on breast-cancer cells. That is the targeting system: it causes the particle to accumulate at the tumour rather than scatter through healthy tissue, which is what limits collateral damage. Second, it is glutathione-responsive, meaning it releases its payload specifically in the high-glutathione chemical environment found inside cancer cells. The carrier is, in effect, locked until it reaches the right address and only then opens.

The payload is two siRNAs at once, targeting MCL-1 and Survivin, two genes that cancer cells exploit to evade apoptosis, the programmed cell death that should normally eliminate damaged or dangerous cells. Cancers are adept at compensating when a single survival pathway is blocked, so silencing two at the same time makes it much harder for the tumour to escape, the conceptual advantage over single-target approaches. The system was tested in MCF-7 breast-cancer cells and in immunodeficient mice, where it produced tumour regression.

Why an Indian public lab matters

The strategic significance is where the work comes from. siRNA therapeutics are a frontier of medicine, the first approved drugs in the class arrived only recently, and the field is dominated by a handful of Western biotech companies whose products are extremely expensive. A complete delivery platform, targeting, protection, triggered release, dual payload, developed inside an Indian government laboratory is therefore two things at once. It is a sovereignty statement, demonstrating capability in a field India has mostly watched from the outside, and it is a potential affordability lever, because owning the platform is the precondition for one day manufacturing such therapies cheaply at home rather than importing them at Western prices.

It also does not stand alone. It rhymes with other recent Indian nanomedicine work, including IIT Madras's silicon-nanotube system for injecting chemotherapy directly into breast-cancer cells, suggesting a genuine and growing competence in targeted drug delivery across the country's public research institutions.

The caveats are the standard and important ones for any preclinical result, and they should temper the enthusiasm. This is an animal-model and cell-line study, years away from human use; the institute's materials described the outcomes qualitatively rather than releasing precise efficacy or dosing figures; and "minimal toxicity" is a preclinical observation in mice, not a clinical finding in people. The translation from a successful mouse experiment to an approved human drug is long, expensive and littered with failures. What ARI has shown is a credible, India-built platform, not a finished medicine. But in a field where the delivery vehicle is most of the battle, demonstrating a working vehicle is precisely the part that matters most.